In January, GlaxoSmithKline announced a series of initiatives for developing new medicines to combat diseases that disproportionately affect the world's poorest countries. The initiatives, which comprise GSK's "open innovation" strategy, were outlined in a speech given by GSK Chief Executive Andrew Witty to the Council on Foreign Relations on January 20th. These initiatives include:
• Making more than 13,500 malaria compounds freely available;
• Establishing new collaborations for sharing IP for treating neglected tropical diseases;
• Pledging to create a sustainable pricing model for a malaria candidate vaccine;
• Providing $8 million in seed funding for an "open lab"; and
• Awarding African Malaria Partnership grants totaling $2.5 million.
To read the full, original article click on this link: Patent Docs: GSK Announces "Open Innovation" Strategy to Combat Neglected Tropical Diseases
Author: Donald Zuhn
